Atopic Dermatitis Drugs Market Size, Share & Growth Report 2032

Atopic Dermatitis Drugs Market: Industry Perspective

The global atopic dermatitis drugs market size was worth around USD 15.19 billion in 2023 and is predicted to grow to around USD 32.50 billion by 2032 with a compound annual growth rate (CAGR) of roughly 8.94% between 2024 and 2032.

Request Free Sample

The report offers a valuation and analysis of the atopic dermatitis drugs market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data.

Atopic dermatitis is a common, serious, and inflammatory skin disorders that largely affect the child population. The inflammatory skin conditions include psoriasis, tinea, erythroderma, and dermatitis. According to NCBI, atopic dermatitis affects nearly twenty percent of children and ten percent of adults in developed nations.  For the record, atopic dermatitis affects nearly 13% of children and 10% of adults in the U.S. Furthermore, the patients and their families have felt a large impact on the quality of life as a well fiscal burden.

The clinical characteristics of atopic dermatitis include excoriations, crusting, erythema, oozing, lichenification, and edema. Additionally, pruritus is the major property of atopic dermatitis and produces comorbidities like mental distress and sleep loss, thereby creating a huge affliction to parents as well as patients. Reportedly, genetic aspects and ecological factors strongly impact atopic dermatitis.

Request Free Sample

Additionally, there is a large occurrence of the disorder in emerging nations. The disease exemplifies massive heterogeneity in the medical severity, disease phenotype, persistence, response to the treatment, and persistence. The key goals of treating the disease through drugs are to reduce inflammation of the skin as well as pruritus and flare prevention.

Market Growth Dynamics

New concepts in disease pathogenesis have prompted research & development activities for creating novel medicines to treat disease.  Additionally, a large spectrum of medicines is utilized for treating skin disease and they include steroids, moisturizing creams, and calcineurin inhibitors. All these beneficial aspects are anticipated to drive the growth of the atopic dermatitis drugs market over the forecast timeline.

Apart from this, the introduction of biologic medicines has helped treat atopic dermatitis. Additionally, new biologic drugs including dupilumab and crisaborole are also used for treating atopic dermatitis. Reportedly, the former drug was first approved for treating atopic dermatitis in adults across regions such as Japan, North America, and Europe.

For the record, dupilumab is the only biologic medicine approved by the European Medicines Agency and the U.S. Food and Drug Administration for treating adult subjects. Moreover, biological medicines can treat adult patients as these drugs provide convenient dose schedules and assist in effective lab monitoring as compared to other forms of systemic treatments along with reduced side effects. All these factors are anticipated to bring a paradigm shift in the atopic dermatitis drugs industry over the forthcoming years.

Atopic Dermatitis Drugs Market: Report Scope

Atopic Dermatitis Drugs Market: Regional Analysis

• North American Market To Acquire Numero Uno Position By 2032

The growth of the regional market over the forecast period is subject to a surge in the incidences of atopic dermatitis in children along with a rise in the frequency of skin allergies in the adult population in countries like the U.S. Apparently, the launching of new drugs in the foreseeable future will further enlarge the business scope over the ensuing years.

Atopic Dermatitis Drugs Market: Competitive Analysis

The global atopic dermatitis drugs market is dominated by players like:

• Meda Pharmaceuticals
• Bayer AG
• Encore Dermatology
• Leo Pharma
• Valent Pharmaceutical Inc.

The global atopic dermatitis drugs market is segmented as follows:

By Therapy

• Photo Therapy
• Directed Therapy

By Route of Administration

• Injectable
• Oral
• Topical

By End-User

• Hospitals
• Clinics
• Research Labs

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa